Shots:
- Remedium Bio has entered into a multi-target research & development collaboration with Eli Lilly to develop gene therapies targeting multiple targets for the treatment of Obesity & Type 2 Diabetes, leveraging Remedium’s Prometheus platform
- As per the deal, Remedium will receive an upfront, equity investment as well as development & commercial milestone payments, with tiered royalties on global net sales; Although financial terms remain undisclosed
- The Prometheus platform enables single-dose, adjustable gene therapies that replace protein treatments, offering tunable control of protein expression with multi-year efficacy at lower cost
Ref: Remedium Bio | Image: Remedium Bio & Eli Lilly | Press Release
Related News:- Biocytogen Partners with Merck KGaA to Develop Antibody-Conjugated Lipid-Based Delivery Solutions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
